Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Activating mutations in Ras oncoproteins are key drivers in many cancers.
• Developing effective cancer immunotherapies targeting Ras mutations remains a challenge due to vector neutralization.
• Few vectors can elicit potent anti-tumor immune responses without being neutralized.

Purpose of the Study:

• To evaluate the efficacy of whole recombinant yeast expressing mutant Ras proteins as a cancer immunotherapy.
• To assess the potential of this yeast-based approach in a carcinogen-induced lung tumor model.

Main Methods:

• Mice with established lung tumors were immunized with whole recombinant yeast heterologously expressing mammalian mutant Ras proteins.
• The study involved a carcinogen-induced lung tumor model in mice.
• Tumor regression was monitored in a dose-dependent and antigen-specific manner.

Main Results:

• Therapeutic immunization with whole recombinant yeast led to complete regression of established lung tumors bearing Ras mutations.
• The observed tumor regression was dose-dependent.
• The immune response was antigen-specific, confirming the targeted nature of the therapy.

Conclusions:

• Whole recombinant yeast expressing mutant Ras proteins is a promising immunotherapeutic strategy for Ras mutation-bearing cancers.
• This approach could be combined with genomic sequencing for personalized treatment of human cancers.
• The yeast-based immunotherapy offers a potential solution to overcome vector neutralization issues in cancer treatment.